Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ$0.414
Market Cap
$15.85M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
493 of 924
Rank in Industry
285 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BOLT Insider Trading Activity
BOLT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist …
Insider Activity of Bolt Biotherapeutics, Inc.
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $0 and sold $0 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $12.4M and sold $622,818 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,500 shares for transaction amount of $7,125 was made by Quinn William P. (Chief Financial Officer) on 2023‑12‑12.
List of Insider Buy and Sell Transactions, Bolt Biotherapeutics, Inc.
| 2023-12-12 | Quinn William P. | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.88% | ||
| 2023-12-06 | Quinn William P. | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.59% | ||
| 2023-11-30 | Sale | ENGLEMAN EDGAR | director | 123,079 0.4308% | $0.86 | $105,614 | -10.81% | |
| 2023-11-29 | Sale | ENGLEMAN EDGAR | director | 25,805 0.0954% | $0.91 | $23,379 | -14.79% | |
| 2023-11-21 | Sale | ENGLEMAN EDGAR | director | 1,943 0.0071% | $0.90 | $1,751 | -10.77% | |
| 2023-11-21 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 3,400 0.0125% | $0.90 | $3,060 | -10.77% | |
| 2023-11-20 | Sale | ENGLEMAN EDGAR | director | 31,257 0.1173% | $0.92 | $28,756 | -15.33% | |
| 2023-11-20 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 54,700 0.2053% | $0.92 | $50,324 | -15.33% | |
| 2023-11-17 | Sale | ENGLEMAN EDGAR | director | 9,345 0.0354% | $0.93 | $8,691 | -16.40% | |
| 2023-11-17 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 16,354 0.062% | $0.93 | $15,209 | -16.40% | |
| 2023-11-16 | Sale | ENGLEMAN EDGAR | director | 8,571 0.0336% | $0.96 | $8,228 | -16.84% | |
| 2023-11-16 | Sale | Vivo Capital VIII, LLC | 10 percent owner | 15,000 0.0587% | $0.96 | $14,400 | -16.84% | |
| 2023-06-06 | Quinn William P. | Chief Financial Officer | 1,829 0.0088% | $1.18 | $2,161 | -31.48% | ||
| 2022-07-13 | Sale | Novo Holdings A/S | 800,000 6.5259% | $2.00 | $1.6M | -40.32% | ||
| 2021-12-08 | Quinn William P. | Chief Financial Officer | 5,000 0.0962% | $4.71 | $23,575 | -56.78% | ||
| 2021-12-06 | Quinn William P. | Chief Financial Officer | 35 0.0007% | $4.64 | $162 | -55.82% | ||
| 2021-12-06 | Perez Edith A. | Chief Medical Officer | 411 0.0078% | $4.64 | $1,907 | -55.82% | ||
| 2021-06-04 | Quinn William P. | Chief Financial Officer | 1,221 0.0829% | $16.65 | $20,330 | -50.69% | ||
| 2021-06-04 | Perez Edith A. | Chief Medical Officer | 917 0.0623% | $16.65 | $15,268 | -50.69% | ||
| 2021-02-09 | Sale | SHAH MAHENDRA | director | 62 0.0051% | $20.00 | $1,240 | -58.82% |
Total: 31
Insider Historical Profitability
<0.0001%
| Novo Holdings A/S | 3703991 9.6778% | $1.53M | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 7.1968% | $1.14M | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 7.1968% | $1.14M | 1 | 0 | <0.0001% |
| ENGLEMAN EDGAR | director | 251522 0.6572% | $104,130.11 | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 0.2918% | $46,228.07 | 1 | 5 | <0.0001% |
Historical Insider Profitability vs. Competitors
$992,222,850 | 90 | -12.52% | $19.2M | |
$8,900,811 | 57 | -24.79% | $15.15M | |
$85,897,100 | 36 | 2.47% | $17.01M | |
$217,684 | 34 | 1.61% | $17.89M | |
$4,368,362 | 28 | -22.35% | $14.54M |
BOLT Institutional Investors: Active Positions
| Increased Positions | 16 | +44.44% | 492,781 | +2.62% |
| Decreased Positions | 10 | -27.78% | 1M | -6.55% |
| New Positions | 10 | New | 422,023 | New |
| Sold Out Positions | 5 | Sold Out | 1M | Sold Out |
| Total Postitions | 42 | +16.67% | 18M | -3.93% |
BOLT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Tang Capital Management Llc | $1,807.00 | 10.03% | 3.81M | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $1,669.00 | 9.27% | 3.52M | 0 | 0% | 2024-12-31 |
| Sofinnova Investments, Inc. | $1,306.00 | 7.25% | 2.75M | 0 | 0% | 2024-12-31 |
| Pivotal Bioventure Partners Investment Advisor Llc | $897.00 | 4.98% | 1.89M | 0 | 0% | 2024-12-31 |
| Nan Fung Group Holdings Ltd | $553.00 | 3.07% | 1.17M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $506.00 | 2.81% | 1.07M | 0 | 0% | 2024-12-31 |
| Samsara Biocapital, Llc | $497.00 | 2.76% | 1.05M | 0 | 0% | 2024-12-31 |
| Board Of Trustees Of The Leland Stanford Junior University | $341.00 | 1.89% | 719,546 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $161.00 | 0.9% | 340,674 | -11,752 | -3.33% | 2024-12-31 |
| Renaissance Technologies Llc | $143.00 | 0.8% | 302,039 | +8,000 | +2.72% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.